EpCAM specific CAR T cells have been developed to treat prostate, breast, and peritoneal cancers and have shown suppressed tumor progression/delayed disease as well as CAR T cell trafficking into the tumor site [273–276]. This evidence concerns the gene EPCAM and neoplasm.